Rapid Dose Therapeutics Corp. (CSE: DOSE)
Canada
· Delayed Price · Currency is CAD 0.240
0.00 (0.00%)
Dec 3, 2024, 4:00 PM EST
Rapid Dose Therapeutics Income Statement
Financials in millions CAD. Fiscal year is March - February.
Millions CAD. Fiscal year is Mar - Feb.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Aug '24 Aug 31, 2024 | Feb '24 Feb 29, 2024 | Feb '23 Feb 28, 2023 | Feb '22 Feb 28, 2022 | Feb '21 Feb 28, 2021 | Feb '20 Feb 29, 2020 | 2019 - 2018 |
| Revenue | 1.34 | 1.02 | 0.72 | 1.75 | 0.76 | 0.1 | Upgrade
|
| Revenue Growth (YoY) | 20.09% | 42.06% | -59.00% | 131.98% | 644.06% | - | Upgrade
|
| Cost of Revenue | 0.55 | 0.46 | 0.36 | 0.41 | 0.13 | 0.06 | Upgrade
|
| Gross Profit | 0.79 | 0.56 | 0.36 | 1.34 | 0.63 | 0.04 | Upgrade
|
| Selling, General & Admin | 3.03 | 2.44 | 2.46 | 2.99 | 1.5 | 4.15 | Upgrade
|
| Research & Development | 0.46 | 0.43 | 0.09 | 0.36 | 0.09 | 0.27 | Upgrade
|
| Operating Expenses | 4.78 | 3.64 | 3.9 | 5.65 | 2.26 | 7.54 | Upgrade
|
| Operating Income | -3.99 | -3.08 | -3.54 | -4.3 | -1.63 | -7.51 | Upgrade
|
| Interest Expense | -0.95 | -0.66 | -0.26 | -0.13 | -0.14 | -0.11 | Upgrade
|
| Interest & Investment Income | - | - | - | 0 | - | 0.02 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.01 | -0.01 | -0 | 0.02 | -0.03 | 0.03 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.15 | - | - | 0.01 | - | 0.09 | Upgrade
|
| EBT Excluding Unusual Items | -4.81 | -3.75 | -3.81 | -4.4 | -1.81 | -7.48 | Upgrade
|
| Impairment of Goodwill | - | - | - | -4.08 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | - | -0.57 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | - | 0.09 | Upgrade
|
| Other Unusual Items | -0.56 | -0.56 | - | - | - | - | Upgrade
|
| Pretax Income | -5.37 | -4.31 | -3.81 | -8.49 | -1.81 | -7.96 | Upgrade
|
| Net Income | -5.37 | -4.31 | -3.81 | -8.49 | -1.81 | -7.96 | Upgrade
|
| Net Income to Common | -5.37 | -4.31 | -3.81 | -8.49 | -1.81 | -7.96 | Upgrade
|
| Shares Outstanding (Basic) | 105 | 105 | 103 | 100 | 78 | 76 | Upgrade
|
| Shares Outstanding (Diluted) | 105 | 105 | 103 | 100 | 78 | 76 | Upgrade
|
| Shares Change (YoY) | -7.40% | 1.50% | 3.19% | 28.83% | 2.23% | 21.26% | Upgrade
|
| EPS (Basic) | -0.05 | -0.04 | -0.04 | -0.08 | -0.02 | -0.10 | Upgrade
|
| EPS (Diluted) | -0.05 | -0.04 | -0.04 | -0.08 | -0.02 | -0.10 | Upgrade
|
| Free Cash Flow | -2.73 | -2.29 | -0.86 | -3.04 | -1.63 | -4.26 | Upgrade
|
| Free Cash Flow Per Share | -0.03 | -0.02 | -0.01 | -0.03 | -0.02 | -0.06 | Upgrade
|
| Gross Margin | 58.64% | 55.21% | 49.67% | 76.76% | 83.40% | 36.79% | Upgrade
|
| Operating Margin | -297.70% | -301.57% | -493.36% | -245.55% | -216.45% | -7394.53% | Upgrade
|
| Profit Margin | -400.10% | -422.03% | -530.42% | -484.47% | -239.04% | -7847.07% | Upgrade
|
| Free Cash Flow Margin | -203.64% | -224.91% | -120.27% | -173.52% | -216.20% | -4193.31% | Upgrade
|
| EBITDA | -3.82 | -2.75 | -3.2 | -3.82 | -1.25 | -7.31 | Upgrade
|
| EBITDA Margin | -284.42% | -269.06% | - | -218.31% | -165.21% | - | Upgrade
|
| D&A For EBITDA | 0.18 | 0.33 | 0.34 | 0.48 | 0.39 | 0.2 | Upgrade
|
| EBIT | -3.99 | -3.08 | -3.54 | -4.3 | -1.63 | -7.51 | Upgrade
|
| EBIT Margin | -297.70% | - | - | -245.55% | -216.45% | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.